Salarius Pharmaceuticals Shares Down 21.6% Premarket as FDA Puts Cancer Drug Trial on Partial Clinical Hold
salarius pharmaceuticals股價在市場開盤前下跌21.6%,因爲FDA將癌症藥物試驗部分暫停。
Salarius Pharmaceuticals Shares Down 21.6% Premarket as FDA Puts Cancer Drug Trial on Partial Clinical Hold
salarius pharmaceuticals股價在市場開盤前下跌21.6%,因爲FDA將癌症藥物試驗部分暫停。
譯文內容由第三人軟體翻譯。